Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins

CA Stone; JA Trubiano; EJ Phillips

Journal article

Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins

CA Stone, JA Trubiano, EJ Phillips

Journal of Allergy and Clinical Immunology in Practice | ELSEVIER | Published : 2021

DOI: 10.1016/j.jaip.2020.07.056

Abstract

Background: Although 1% to 2% of the general population carries a cephalosporin allergy label (CAL), we lack validated testing strategies and predictors of true allergy. Objective: To identify cross-reactivity patterns and predictors of skin test positive (STP) in geographically disparate patients with a CAL. Methods: A total of 780 adult patients labeled with a CAL or penicillin allergy label (PAL) with unknown tolerance of cephalosporins identified from the Austin Hospital (Melbourne, Australia) (n = 410) and Vanderbilt University Medical Center (Nashville, TN) (n = 370) between 2014 and 2018 underwent a standardized skin testing. Results: Of 328 patients with a CAL, 29 (8.8%) tested STP t..

View full abstract

University of Melbourne Researchers

Jason Trubiano Author

Related Projects (2)

NATIONAL CENTRE FOR INFECTIONS IN CANCER (NCIC)

This Centre of Research Excellence will translate the best available evidence to improve cancer outcomes through better management of infect..

DEVELOPING AND EVALUATING A MULTIMODAL ANTIBIOTIC ALLERGY STRATEGY TO IMPROVE ANTIMICROBIAL STEWARDSHIP IN HIGH-RISK ANTIBIOTIC USAGE POPULATIONS

Antibiotic allergies lead to the use of inferior antibiotics and generation of “superbugs”. Antibiotic allergy testing removes up to 90% of ..

Grants

Awarded by Agency for Healthcare Research and Quality

Funding Acknowledgements

C. A. Stone receives funding from AHRQ 1K12HS026395-01, and was also funded by NIH/NHLBI T32 HL87738 and NIH/NIGMS T32 GM007569 during this project. J. A. Trubiano receives funding from National Health and Medical Research Council (NHMRC) postgraduate scholarship (GNT 1139902) and a postgraduate scholarship from the National Centre for Infections in Cancer, National Health and Medical Research Council, and BHF Centre of Research Excellence, Oxford (GNT 1116876). E. J. Phillips receives funding from National Institutes of Health (1P50GM115305-01, R21AI139021, and R34AI136815) and the National Health and Medical Research Foundation of Australia.